1-2 of 2
Venu Menon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

Free
Nishant P. Shah, Qiuqing Wang, Katherine E. Wolski, Leslie Cho, Ellen McErlean, Giacomo Ruotolo, Govinda Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen, Venu Menon
Journal: Diabetes Care
Diabetes Care 2020;43(2):e22–e24
https://doi.org/10.2337/dc19-1117
Published: 05 December 2019
View articletitled, The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE
Open the PDF for The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE in another window
Journal Articles

Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial

Free
Venu Menon, A. Michael Lincoff, Stephen J. Nicholls, Susan Jasper, Kathy Wolski, Darren K. McGuire, Cyrus R. Mehta, Julio Rosenstock, Claudia Lopez, John Marcinak, Charlie Cao, Steven E. Nissen
Journal: Diabetes Care
Diabetes Care 2018;41(12):2603–2609
https://doi.org/10.2337/dc18-0755
Published: 12 November 2018
View articletitled, Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial
Open the PDF for Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial in another window
Includes: Supplementary data